TSE:3349Consumer Retailing
Cosmos Pharmaceutical (TSE:3349) Stock Faces Thin 2.9% Margin Challenging Defensive Retail Narrative
COSMOS Pharmaceutical (TSE:3349) has wrapped up FY 2026 with fourth quarter revenue of ¥289.2b and basic EPS of ¥117.31, set against trailing twelve month revenue of ¥1.10t and EPS of ¥404.33 as earnings rose 3.4% over the past year. Over recent periods the company has seen revenue move from ¥1.01t to ¥1.10t on a trailing basis, while basic EPS has shifted from ¥390.85 to ¥404.33. Net profit margins stand at 2.9% versus 3.1% the year before.
See our full analysis for COSMOS...